Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Caribou Biosciences, Inc. (CRBU)

Caribou Biosciences Q3 loss narrows to $26.6 million; two programs being discontinued

Negative Impact 4 of 5 restructuring Written later

Caribou Biosciences reported third quarter 2026 results with a net loss of $26.6 million, or $0.25 per share, compared with $27.5 million, or $0.30 per share, a year earlier, while licensing revenue fell to $1.6 million from $2.2 million. The company also disclosed an October 6, 2026 restructuring: it plans to discontinue clinical trials and development of vispa-cel and CB-011, cut its workforce substantially, and explore strategic alternatives that may include a merger or dissolution and liquidation, with no timeline set.

Key points

  • Q3 2026 net loss was $26.6 million, or $0.25 per share, versus $27.5 million, or $0.30 per share, in Q3 2025.
  • Licensing and other third-party revenue was $1.6 million, down from $2.2 million.
  • Cash, cash equivalents, and marketable securities were $94.8 million at September 30, 2026, down from $142.8 million at December 31, 2025.
  • The October 6, 2026 restructuring includes discontinuing vispa-cel and CB-011 and a substantial workforce reduction; the company has not set a timeline for its strategic review.

The filing

CompanyCaribou Biosciences, Inc. (CRBU)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:07 PM ET
Accession number0001619856-26-000060

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.